- Coordinator
- Universite Catholique De Louvain, Belgium
- Runs
- 1 July 2024 to 31 December 2025
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101158056
What the project is doing
In the project's own words, from its summary on CORDIS.
HormoCaps will help us demonstrate the viability as a commercial product of a dual-action drug delivery system which synergizes its own biological effect and that of the encapsulated bioactive molecule for the oral delivery of peptides. This would represent an alternative to current oral incretin-based treatments for gastrointestinal metabolic disorders. In HormoCaps, we will (i) demonstrate the translational feasibility of our strategy; (ii) evaluate the capacity of the formulation to simultaneously stimulate the secretion of hormones that are present at different concentrations at distinct regions of the gastrointestinal mucosa; and (iii) consolidate our results towards a licensing plan to guide the commercialization of our formulation.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universite Catholique De Louvain | Louvain La Neuve | Belgium | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI